Table 4.
EC50 (μM, n≥4) values for potentiation of GluN1/GluN2 NMDAR subtypesa
| Compounds | GluN2A | GluN2B | GluN2C | GluN2D |
|---|---|---|---|---|
| 14a | 26.7 ± 5.6 (39.0 ± 5.9) |
ND | 113 ± 66 (42.7 ± 16.1) |
61 ± 33 (17.3 ± 16.2) |
| 14b | 28.0 ± 4.6 (68.6 ± 16.2) |
34.6 ± 3 (102.0 ± 17.8) |
37.2 ± 2.8 (117.2 ± 22.3) |
28.9 ± 4.1 (88.4 ±9.6) |
| 27b | 7.5 ± 2.8 (38.4 ±4.7) |
27.0 ± 6.3 (61.9 ± 10.9) |
22.4 ± 3.6 (105.3 ± 26.1) |
34.7 ± 10.3 (65.6 ± 18.4)) |
| 44 | 114.4 ± 7.2 (230.4 ± 84.6) |
116.4 ± 19.8 (416.6 ± 70.9) |
26.1 ± 4.5 (136.6 ± 11.6) |
72.3 ± 15.5 (277.2 ± 36.8) |
| 46 | 39.4 ± 27.5 (277.2 ± 36.8) |
25.0 ± 11.6 (192.3 ± 46.6) |
36.2± 5.7 (262.6 ± 33.9) |
30.6 ± 7.5 (240.3 ± 63.6) |
a
EC50 values (mean ± s.e.m.) for the potentiation of GluN1/GluN2 NMDAR responses responses. Values in parenthesis are the maximum potentiation expressed as a percentage (± s.e.m.) above the agonist alone response (L-glutamate, 10 μM and glycine, 10 μM). ND = not determined.